Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
IN

INSM

Market Closed

Insmed Incorporated

NASDAQHealthcareBiotechnology
US
1.66K employees
CEO: William H. Lewis
Founded: 2000
$124.36
+$0.00(+NaN%)
Market Cap
27.28B
Beta
0.81
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Insmed's current price exceeds the PERT fair value by 19%, with high-confidence valuations signaling possible overvaluation versus intrinsic worth, particularly as DCF indicates significant negative mid-values. Strong liquidity and growth contrast with zero profitability and efficiency scores, reflecting financial health risks. The Monte Carlo analysis shows minimal downside risk below current price, highlighting price resilience despite valuation concerns.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore INSM

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

INSM in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →